Molecular mechanisms controlling human melanoma progression and metastasis

Pathobiology

Volumn 65, Issue 6, 1996, Pages 311-330

  Welch, Danny R ^a   Goldberg, Steven F ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

6; 7; 9 11; Chromosomes 1; Cytogenetics; Genetics; Melanoma; Metastasis; Tumor progression

Indexed keywords

CANCER STAGING; CANCER SUSCEPTIBILITY; CELL STRUCTURE; CHROMOSOME 1; CHROMOSOME 10; CHROMOSOME 11; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 9; DISEASE COURSE; HUMAN; MELANOCYTE; MELANOMA; METASTASIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

EID: 0031461745     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000164143     Document Type: Article

References (288)

1. Rigcl DS., Kopf AW., Friedman RJ: The rate of malignant melanoma in the United States: Are we making an impact? J Am Acad Dermatol 1987:17:1050-1053.
2. Koh UK: Cutaneous melanoma., N Hngl J Med 1991;325:171-182.
3. Rigcl DS: The gender-related issues in malignant melanoma., Hawaii Med J 1993:52:124-146.
4. Cannon-Albright LA., Kamb A, Skolnick M: A review of inherited predisposition to melanoma., Semin Oncol 1996:23:667-672.
5. Greene MH: Genetics of cutaneous melanoma and nevi., Mayo Clin Proc 1997:72:467-474.
6. Haluska FG., Housman DE: Recent advances in the molecular genetics of malignant melanoma., Cancer Surv 1995;25:277-292.
7. Kraehn GM., Schartl M., Peter RU: Human malignant melanoma: A genetic disease., Cancer 1995:75:1228-1237.
8. Fountain JW., Bale SJ., Housman DF., Draco-poli NC: Genetics of melanoma., Cancer Sun 1990;9:645-671.
9. Greene MH., Fraumcni JF: The hereditary variant of malignant melanoma; in Clark WH., Goldman LI., Mastrangelo MJ (cds): Human Malignant Melanoma., New York, Grune & Stratton., 1979., pp 139-166.
10. Urist MM., Karnell LH: The National Cancer Data Base: Report on melanoma., Cancer 1994; 74:782-788.
11. Norris W: A ease of fungoid disease., Edinb MedSurgJ 1820:16:562-565.
12. Cawley EP: Genetic aspects of malignant melanoma., AMA Arch Dermatol 1952:65:440-450.
13. Cawley EP: Genetic aspects of malignant melanoma., AMA Arch Dermatol Syphilol 1951;65: 440-450.
14. Dracopoli NC., Bale SJ: Genetic aspects of cutaneous malignant melanoma., Semin Oncol 1988:15:541-548.
15. Kacker RK., Giovanella BC., Pathak S: Consistent karyotypic abnormalities in human malignant melanomas., Anticanccr Res 1990:10: 859-871.
16. Meyer LJ., Zone JH: Genetics of cutaneous melanoma., J Invest Dermatol 1994: 103(suppl):l 12S-116S.
17. Newton JA: Genetics of melanoma., Br Med Bull 1994:50:677-687.
18. Piepkom MW: Genetic basis of susceptibility to melanoma., J Am Acad Dermatol 1994:31: 1022-1039.
19. Skolnick MH., Cannon-Albright LA., Kamb A: Genetic predisposition to melanoma., Eur J Cancer 1994;30A: 1991-1995.
20. Tucker MA., Fraser MC., Goldstein AM., Elder DE., Gucrry DP., Organic SM: Risk of melanoma and other cancers in melanoma-prone families., J Invest Dermatol 1993:100:350S-355S.
21. Haines JL., Trofatter JA: Genetic linkage and affected pedigree member analysis in malignant melanoma., Cancer Genet Cytogenct 1992:59:206-207.
22. Lynch HT, Fusaro RM: The surgeon, genetics and malignant melanoma, Arch Surg 1992: 127:317-319.
23. Risch N, Sherman S: Genetic analysis workshop 7: Summary of the melanoma workshop, Cancer Genet Cytogenet 1992;59:148-158.
24. Gordon M: The genetic concept for the origin of melanomas., Ann NY Acad Sci I958;71: 1213-1220.
25. Clark WH., Reimer RR., Green M., Ainsworth AM., Mastrangelo MJ: Origin of familial malignant melanomas from heritable mclanocytic lesions., Arch Dermatol 1978; 1 14:732-738.
26. Lynch HT, Frichot BC, Lynch JF: Familial atypical multiple mole-melanoma syndrome., J Med Genet 1978:15:352-356.
27. Easton D: The role of atypical mole syndrome and cutaneous naevi in the devclopcnt of melanoma., Cancer Surv 1996:26:237-249.
28. Bishop JAN: Molecular pathology of melanoma., Cancer Metastasis Rev 1997;16:141-154.
29. Piepkorn ME., Barnhill RL, Cannon-Albright LA., Elder DE., Goldgar DE, Lewis CM., Maize JC., Meyer U., Rabkin MS., Sagebiel RW., Skon-ick MH., Zone J J: A multiobscrver., population-based analysis of histologic dysplasia in mclanocytic nevi., J Am Acad Dermatol 1994:30: 807-810.
30. Helm KF., Marks JG: Atlas of Differential Diagnosis in Dermatology., New York., Churchill Linvingston., 1997.
31. Farmer ER., Gonin R., Hanna NP: Discordance in the histopathologic diagnosis of melanoma and mclanocytic nevi between expert pathologists., Hum Pathol 1996:27:528-531.
32. Carey WP Jr., Thompson CJ., Synnestvedt M., Guerry D., Halpcrn A., Schultz D., Elder DE: Dysplastic nevi as a melanoma risk factor in patients with familial melanoma., Cancer 1994: 74:31 18-3125.
33. Harnett PR, Keltord RF: Molecular models of tumorigenesis: Application to familial and sporadic melanoma., Semin Oncol 1988:15:549-557.
34. Cheng KC., Loeb LA: Genomic instability and tumor progression: Mechanistic considerations., Adv Cancer Res 1993:60:121-156.
35. Cuthill S: Cellular cpigenctics and the origin of cancer., Bioessays 1994;16:393-394.
36. lannacconc PM., Weinberg WC., Deamant FD: On the clonal origin of tumors: A review of experimental models., Int J Cancer 1987;39: 778-784.
37. Tlsty TD., Jonczyk P., White A., Sage M., Hall I., Schaefer D, Briot A, Livanos E., Roelofs H., Poulose B., Sanchez J: Loss of chromosomal integrity in neoplasia., Cold Spring Harbor Symp Quant Biol 1993:58:645-654.
38. Welch DR., Tomasovic SP: Implications of tumor progression on clinical oncology., Clin Exp Metastasis 1985;3:151-188.
39. Miller FR, Heppner GH: Cellular interactions in metastasis., Cancer Metastasis Rev 1990:9: 21-34.
40. Vogelstein B., Fearon ER., Hamilton SR., Kern SE, Prcisinger AC., Leppert M., Nakamura Y., White R., Smits AMM, Bos JL: Genetic alterations during colorectal tumor development., N Engl J Med 1990:319:525-532.
41. Kinzler KW, Nilbert MC, Vogelstein B., Bryan TM., Levy DB., Smith K.I., Preisinger AC., Hamilton SR, Hedge P., Markham A, Carlson M., Joslvn G., Groden J., White R., Miki Y., Miyoshi Y., Nishisho I., Nakamura Y: Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers., Science 1991:251: 1366-1370.
42. Nishisho I, Nakamura Y, Miyoshi Y., Miki Y., Ando H., Horii A., Koyama K, Utsunomiya J., Baba S., Hedge P., Markham A, Krush AJ., Petersen G., Hamilton SR., Nilbert MC., Levy DB., Bryan TM., Preisinger AC., Smith KJ., Su L-K, Kinzler KW, Vogelstein B: Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients., Science 1991;253:665-670.
43. Isaacs WB., Bova GS., Morton RA., Bussemak-ers MJG., Brooks JD., Ewing CM: Molecular biologv of prostate cancer progression., Cancer Sun 1995;23:19-32.
44. Ware JL: Prostate cancer progression: Implications of histopathology., Am J Pathol 1994:145: 983-993.
45. Welcrman MAJ., Van Muijen GNP., Bloemers HPJ., Ruiter D.I: Molecular markers of nielano-cvtic tumor progression., Lab Invest 1994:70: 593-608.
46. Folberg R: Tumor progression in ocular melanomas., J Invest Dermatol 1993:100:326S-33 1S.
47. Van de Vijver MJ: Molecular genetic changes in human breast cancer., Adv Cancer Res 1993: 61:25-56.
48. Mooi WJ, Petcrse JL: Progress in molecular biology of breast cancer., Eur J Cancer 1992:28: 626-635.
49. Clark WH., Elder DE., Guerry D., Brailman LE., Trock BJ, Schultz D., Synnestvedt M., Halpcrn AC: Model predicting survival in stage I melanoma based upon tumor progression., J Natl Cancer Inst 1989:81:1893-1904.
50. Neshal K, Sanchez CA., Galipeau PC., Cowan DS., Ramcl S., Levine DS., Reid BJ: Barrett’s esophagus: A model of human neoplastic progression., Cold Spring Harbor Symp Quant Biol 1994;59:577-584.
51. Welch DR: Technical considerations for studying cancer metastasis in vivo., Clin Exp Metastasis 1997:15:272-306.
52. Nicolson GL: Growth mechanisms and cancer progression., HospPract 1993:28:43-53.
53. Lindblom A, Linder S: The metastatic phenotype-prognostic implications., Crit Rev Oncol Hetnalol 1996:24:71-96.
54. von Stein OD., Thies W-G., Hofmann M: A high throughput screening for rarely transcribed differentially expressed genes., Nucleic Acids Res 1997;25:2598-2602.
55. Wright JA., Egan SE., Greenberg AH: Genetic regulation of metastatic progression., Anticancer Res 1990:10:1247-1256.
56. Nicolson GL: Gene expression, cellular diversification and tumor progression to the metastatic phenotype., Bioessays 1991;13:337-342.
57. Dear TN., Kcftord RF: Molecular oncogenetics of metastasis., Mol Aspects Med 1990:11:243-324.
58. Chambers AF: Mechanisms of oncogene-mediated alterations in metastatic ability., Bio-chem Cell Biol 1992;70:817-821.
59. Egan SE, Wright J A., Greenberg AH: Molecular determinants of metastatic transformation., Environ Health Perspect 1991:93:91-95.
60. Fidlcr IJ., Radinsky R: Genetic control of cancer metastasis., J Natl Cancer Inst 1990:82: 166-168.
61. zur Hausen H., De Villicrs E-M: Human papillomaviruses., Annu Rev Microbiol 1994:48: 427-447.
62. Body D: Invasion and metastasis., Cancer Metastasis Rev 1996:15:77-89.
63. Jiang WG., Puntis MCA., Hallctt MB: Molecular and cellular basis of cancer invasion and metastasis: Implications for treatment., Br J Surg 1994:81:1576-1590.
64. Fidlcr IJ., Ellis LM: The implications of angiogenesis for the biology and therapy of cancer metastasis., Cell 1994:79:185-188.
65. Liotta LA: Cancer cell invasion and metastasis., SciAm 1992;266:54-63.
66. Dickson RB., Lippman ME: Molecular determinants of growth., angiogenesis and metastasis in breast cancer Semin Oncol 1992:19:286-298.
67. Steeg PS: Search for metastasis suppressor genes., Invasion Metastasis 1989:9:351-359.
68. Sobel ME: Metastasis suppressor genes., J Natl Cancer Inst 1990:82:267-276.
69. Liotta LA., Stetler-Stevenson WG: Tumor invasion and metastasis: An imbalance of positive and negative regulation., Cancer Res 1991:51: 5054s-5059s.
70. Steeg PS., De La Rosa A., Flatow U., MacDonald NJ., Benedict M., Leone A: Nm23 breast cancer metastasis., Breast Cancer Res Treat 1993:25: 175-187.
71. Welch DR., Chen P., Miele ME, McGary CT., Bower JM, Weissman BE., Stanbridge EJ: Mi-crocdl-mcdiatcd transfer of chromosome 6 into metastatic human C8I61 melanoma cells suppresses metastasis but does not inhibit tu-morigcnicity., Oncogene 1994:9:255-262.
72. Kamb A, Gruis NA, Wcaver-Feldhaus J, Liu Q., Harshman K., Tavtigian SV., Stockert F., Day RS III., Johnson BE., Skolnick Mil: A cell cycle regulator potentially involved in genesis of many tumor types., Science 1994:264:436-440.
73. Nobori T., Miura K., Wu DJ., Lois A., Takabaya-shi K., Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers., Nature 1994:368:753-756.
74. Kama A, Shattuck-Eidens D, Eeles R., Liu Q, Gruis NA., Ding W., Hussey C., Tran T., Miki Y., Weavcr-Feldhaus J., McClure M., Aitken JF., Anderson DE., Bergman W., Frants R., Goldgar DE, Green A, MacLennan R, Martin NG., Meyer LJ., Youl P., Zone JJ., Skolnick MH., Can-non-Albright LA: Analysis of the pi6 gene (CDKS2) as a candidate for the chromosome 9p melanoma susceptibility locus., Nature Genet 1994;8:22-26.
75. Hussussian CJ., Struewing JP., Goldstein AM., Higgins PAT., Ally DS., Shcahan MD., Clark WH Jr., Tucker MA., Dracopoli NC: Germline pl6 mutations in familial melanoma., Nature Genet 1994;8:15-21.
76. Walker GJ., Hussussian CJ., Flore JF., Glcndcn-ing JM, Haluska FG, Dracopoli NC., Hayward NK., Fountain JW: Mutations of the CDKN2/ p!6IN’KJ gene in Australian melanoma kindreds., Hum Mol Genet 1995:4:1845-1852.
77. Walker GJ, Palmer JM, Walters MK, Hayward NK: A genetic model of melanoma tumorigenesis based on allelic losses., Genes Chromosomes Cancer 1995:12:134-141.
78. Healy E., Rehman I, Angus B, Rees JL: Loss of heterozygosity in sporadic primary cutaneous melanoma., Genes Chromosomes Cancer 1995: 12:152-156.
79. Healy E., Belgaid CE., Takala M., Vahlquist A, Rehman I., Rigby H., Rees JL: Allelotypes of primary cutaneous melanoma and benign me-lanocytic nevi., Cancer Res 1996:56:589-593.
80. Greene MH., Goldin LR., Clark WH., Lovrien E., Kraemer Kll, Tucker MA., Elder DE., Fraser MC., Row’e S: Familial cutaneous malignant melanoma: Autosomal dominant trait possibly linked to the Rh locus., Proc Natl Acad Sci USA 1983:80:6071-6075.
81. Bale SJ., Dracopoli NC., Tucker MA., Clark WH., Fraser MC, Stanger BZ, Green P., Donis-Keller H., Housman DE, Greene MH: Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome lp., N Engl J Mcd 1989:320:1367-1372.
82. Fountain JW., Graw SL., Kao W., Stanton VP., Aburatani H, Munroe DJ., Jackson CL., Draco-poli NC., Housman DF.: Further characterization of the 9p21 region frequently deleted in human cutaneous melanoma., Am.1 Hum Genet 1992;54:A51.
83. Fountain JW., Karayiorgu M., Emstoff MS, Kirkwood JM., Vlock DR., Titus-Emstoff L., Bouchard B., Vijavasaradhi S., Houghton AN, Lahti J., Kidd VJ, Housman DE., Dracopoli NC: Homozygous deletions within human chromosome band 9p2l in melanoma., Proc Natl Acad Sci USA 1992:89:10557-10561.
84. Cannon-Albright LA., Goldgar DE., Wright EC., Turco A., Josl M., Meyer LJ, Piepkom M., Zone JJ., Skolnick MH: Evidence against the reported linkage of the cutaneous melanoma-dys-plastic nevus syndrome to chromosome 1 p36., Am J Hum Genet 1990:46:912-918.
85. Oku N., Koike C, Tokudomc Y, Okada S., Nishikawa N., Tsukada H., Kiso M., Hascgawa A., Fujii H., Murata J., Saiki I: Application of liposomes for cancer metastasis., Adv Drug De-livRev 1997;24:215-223.
86. KctTord RF., Salmon J, Shaw HM., Donald JA, McCarthy WH: Hereditary melanoma in Australia: Variable association with dvsplastic nevi and absence of genetic linkage to chromosome lp., Cancer Genet Cytogenel 1991:51:45-55.
87. Goldstein AM., Goldin LR., Dracopoli NC., Clark WH Jr, Tucker MA: Two-locus linkage analysis of cutaneous malignant melanoma/ dvsplastic nevi., Am J Hum Genet 1996:58: 1050-1056.
88. Dracopoli NC., Harnett PR., Bale SJ., Stanger BZ., Tucker MA., Housman DE., KelTord RF: Loss of alleles from the distal short arm of chromosome 1 occurs late in melanoma tumor progression., Proc Natl Acad Sci USA 1989:86: 4614-4618.
89. Miele ME., Robertson G., Lee JH., Coleman A., McGarv CT., Fisher PB., Lugo TG., Welch DR: Metastasis suppressed, but lumorigenicitv and local invasiveness unaffected, in the human melanoma cell line MelJuSo after introduction of human chromosomes I or 6., Mol Carcinog 1996:15:284-299.
90. Liu Q., Neuhausen S., McClure M., Frye C., Weaver-Feldhaus J., Gruis NA., Eddington K., Allalunis-Turncr MJ., Skolnick MH., Fujimura FK., Kanib A: CDKN2 (MTS I) tumor suppressor gene mutations in human tumor cell lines., Oncogene 1995:10:1061-1067.
91. Liu L, Lassam N.I., Slingerland JM., Bailey D., Cole D., Jenkins R., Hogg D: Germlinepl6, SK4A mutation and protein dysfunction in a family with inherited melanoma., Oncogene 1995:11: 405-412.
92. Wick ST., Dubav MM., Imanil I., Brizuela L.: Biochemical and mutagenic analysis of the melanoma tumor suppressor gene product pi 6., Oncogene 1995; 11:2013-2019.
93. Dracopoli NC., Fountain JW: CDKN2 mutations in melanoma., Cancer Sun 1996:26:115-132.
94. Matlandsmo GM., Florencs VA., Hovig E., Oy-jord T., Engcbraaten O., Holm R., Borresen AL, Fodstad O: Involvement of the pRb/p!6/ cdk4/cyclin D1 pathway in the tumorigencsis of sporadic malignant melanomas., Br J Cancer 1996:73:909-916.
95. Borg A., Johansson U., JohannssonO., Hikans-son S., Wcsterdahl J., Misback A, Olsson H., Ingvar C: Novel germline pl6 mutation in familial malignant melanoma in southern Sweden., Cancer Res 1996:56:2497-2500.
96. Gruis NA, Sandkuijl LA., Van dcr Veldcn PA., Bergman W., Frants R: CDKN2 explains part of the clinical phenotype in familial multiple mole melanoma (FAMMM) syndrome families., Melanoma Res 1995;5:169-177.
97. Piccinin S., Doglioni C., Maestro R., Vukosav-Ijevic T., Gasparotto D., D’Orazi C., Boiocchi M: p6CDK.:2and CDK4 gene mutations in sporadic melanoma development and progression., Ini J Cancer 1997:74:26-30.
98. Puig S., Ruiz A., Lazaro C., Castel T., Lynch M., Palou J, Vilalta A., Weissenbach J, Mascaro J-M., Estivill X: Chromosome 9p deletions in cutaneous malignant melanoma tumors: The minimal deleted region involves markers outside the p6 (CDKN2) gene., Am J Hum Genet 1995;57:395-402.
99. Glendening JM., Flores JF, Walker GJ., Stone S., Albino AP., Fountain JW: Homozygous loss of the pl5INKJb gene (and not the p 16INiKJ gene) during tumor progression in sporadic melanoma patients., Cancer Res 1995:55: 5531-5535.
100. Trent JM: Cytogenetics of human malignant melanoma., Cancer Metastasis Rev 1991:10: 103-113.
101. Dracopoli NC., Sam B., Fountain JW., Schartl M: A homolog of the Xiphophorus melanoma-inducing locus Xntrk maps to 6q27., a region frequently involved in rearrangements and deletions in human melanomas., Am J Hum Genet 1992:54:A51.
102. Trent JM., Thompson FH., Meyskcns FL: Identification of a recurring translocation site involving chromosome 6 in human malignant melanoma., Cancer Res 1989;49:420-423.
103. Guan X-Y., Meltzer PS., Cao J., Trent JM: Rapid generation of region-specific genomic clones by chromosome microdissection: Isolation of DNA from a region frequently deleted in malignant melanoma., Genomics 1992:14:680-684.
104. Millikin D., Meese E, Vogclstcin B, Witkow-ski C., Trent JM: Loss of heterozygosity for loci on the long arm of chromosome 6 in human malignant melanoma., Cancer Res 1991:51:5449-5453.
105. Trent JM., Standbridge EJ., McBride HL., Meese EU., Casey G., Araujo DE., Witkowski CM, Nagle RB: Tumorigenicily in human melanoma cell lines controlled by introduction of human chromosome 6., Science 1990: 247:568-571.
106. Robertson GR., Coleman AC., Kanakaraj K., Ramos J, Stanbridge El, Lugo TG: Rcintro-duction of chromosomes 1, 6 and 9 into human malignant melanoma cells., Proc Am Assoc Cancer Res 1994,35:1119.
107. Church SL: Manganese superoxide dismu-tase: Nucleotide and deduced amino acid sequence of a cDNA encoding a new human transcript., Biochim Biophys Acta 1990:1087: 250-252.
108. Ray ME., Su YA, Meltzer PS, Trent JM: Isolation and characterization of genes associated with chromosome-6 mediated tumor suppression in human malignant melanoma., Oncogene 1996:12:2527-2533.
109. Su YA, Ray ME, Lin T., Seidel NE, Bodine DM., Meltzer PS., Trent JM: Reversion of monochromosome-mediatcd suppression of tumorigenicity in malignant melanoma by retroviral transduction., Cancer Res 1996:56: 3186-3191.
110. Welch DR., Ncri A., Nicolson GL: Comparison of ’spontaneous’ and ’experimental’ metastasis using rat 13762 mammary adenocarcinoma cell clones., Invasion Metastasis 1983: 3:65-80.
111. O’Reilly MS., Holmgren L., Shing Y., Chen C, Rosenthal RA., Moses M, Lane WS, Cao Y., Sage EH., Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma., Cell 1994:79:315-328.
112. Welch DR., Bisi JE., Miller BE., Conaway D., Seftor EA, Yohern KH., Gilmore LB, Seftor RE8., Nakajima M., Hendrix MJC: Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line., Int J Cancer 1991;47:227-237.
113. Johnson JP., Dcmmer-Dieckmann M., Meo T., Hadani MR., ReithmullcrG: Surface antigens of human melanoma cells defined by monoclonal antibodies., 1., Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin., Eur J Immunol 1981:11:825-831.
114. Claas C., Herrmann K., Matzku S., Moller P., Zoller M: Developmentally regulated expression of metastasis-associated antigens in the rat., Cell Growth Differ 1996;7:663-678.
115. Lee J-H, Miele ME., Hicks DJ., Phillips KK., Trent JM., Weissman BE., Welch DR: KiSS-1., a novel human malignant melanoma metastasis-suppressor gene., J Natl Cancer Inst 1996: 88:1731-1737.
116. Jiang H., Lin J., Su Z, Hcrlyn M, Kerbel RS, Weissman BE., Welch DR., Fisher PB: The melanoma differentiation-associated gene mda-6., which encodes the cyclin-depcndent kinase inhibitor p2l., is differentially expressed during growth, differentiation and progression in human melanoma cells., Oncogene 1995:10:1855-1864.
117. You J., Miele ME., Dong C., Welch DR: Suppression of human melanoma metastasis by introduction of chromosome 6 may be partially due to inhibition of motility, but not to inhibition of invasion., Biochem Biophys Res Commun 1995:208:476-484.
118. Chambers AF. Matrisian LM: Changing views of the role of matrix metalloprotcinases in metastasis., J Natl Cancer Inst, in press.
119. Khokha R, Waterhouse P, Yagel S., Lala PK., Overall CM., Norton G., Denhardt DT: Anti-sense RNA-induced reduction in murine T1MP levels confers oncogenicity on Swiss 3T3 cells., Science 1989:243:947-950.
120. Khokha R: Suppression of the umorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of metalloprotcinases-1., J Natl Cancer Inst 1994;86:299-304.
121. DcClerck YA., Perez N., Shimada H., Boone TC., Langley KE., Taylor SM: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases., Cancer Res 1992:52:701-708.
122. Khokha R., Zimmer MJ., Graham CH., Lala PK, Waterhouse P: Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-I) in B16-F10 melanoma cells., J Natl Cancer Inst 1992:84: 1017-1022.
123. Church SL., Grant JW., Meese EU., Trent JM: Sublocalization of the gene encoding manganese superoxide dismutasc (MnSOD/SOD2) to 6q25 by fluorescence in situ hybridization and somatic cell hybrid mapping., Genomics 1992:14:823-825.
124. Church SL., Grant JW., Ridnour LA., Obcrley LW., Swanson PE., Meltzcr PS., Trent JM: Increased manganese superoxide dismutase expression suppresses the malignant phenotype of human melanoma cells., Proc Natl AcadSci USA 1993:90:3113-3117.
125. Mielc ME., Welch DR: Transfection of SOD2 into a highly metastatic human melanoma cell line C8161 does not alter tumorigenicity or metastatic ability., Proc Am Assoc Cancer Res 1995:36:455.
126. Fisher PB., Prignoli DR., Hcrmo H., Weinstein IB, Pestka S: Effects of combined treatment with interferon and mczcrcin on melanogene-sis and growth of human melanoma cells., J Interferon Res 1985:5:11-22.
127. Jiang H, Su Z-Z., Boyd J., Fisher PB: Gene expression changes associated with reversible growth suppression and the induction of terminal differentiation in human melanoma cells., Mol Cell Differ 1993;1:41-66.
128. Jiang H., Fisher PB: Use of a highly sensitive and efficient subtraction hybridization protocol for the identification of genes differentially regulated during the induction of differentiation in human melanoma cells., Mol Cell Differ 1993:1:285-299.
129. Jiang H., Lin J., Fisher PB: A molecular definition of terminal cell differentiation in human melanoma cells., Mol Cell Differ 1994:2:221-239.
130. Lee J-H, Welch DR: Identification of highly expressed genes in metastasis-suppressed chromosome 6/human malignant melanoma hybrid cells using subtractive hybridization and differential display., Int J Cancer 1997: 71:1035-1044.
131. Lee J-H., Welch DR: Suppression of metastasis in human breast carcinoma MDA-MB-435 cells after transfection with the metastasis suppressor gene, KiSS-1., Cancer Res 1997; 57:2384-2387.
132. Torp SH, Helseth F., Ryan L., Stolan S., Dalen A., Unsgaard G: Amplification of the epidermal growth factor receptor gene in human gliomas., Anticancer Res 1991:11:2095-2098.
133. Koprowski H., Herlyn M., Balaban G., Parmit-er AH, Ross A., Nowell PC: Expression of the receptor for epidermal growth factor correlates w ith increased dosage of chromosome 7 in malignant melanoma., Somat Cell Mol Genet 1985:11:297-302.
134. de Wit PE., Moretti S., Koenders PG., Weter-man MA., van Muijen GN., Gianotti B., Ruiter DJ: Increasing epidermal growth factor receptor expression in human mclanocytic tumor progression., J Invest Dermatol 1992:99:168-173.
135. Tsarfaty I., Resau JH., Rulong S., Keydar I., Fal-etto DL., Vande Woude GF: The me proto-oncogene receptor and lumen formation., Science 1992:257:1258-1261.
136. Kenworthy P, Dowrick P., Baillie-Johnson H., McCann B., Tsubouchi H., Arakaki N., Daiku-hara Y., Warn RM: The presence of scatter factor in patients with metastatic spread to the pleura., BrJ Cancer 1992:6:243-247.
137. Park M., Testa JR., Blair DG., Parsa NZ., Vande Woude GF: Two rearranged MET alleles in MNNG-HOS cells reveal the orientation of MET on chromosome 7 to other markers tightly linked to the cystic fibrosis locus., Proc Natl Acad Sci USA 1988:85:2667-2671.
138. Rodeck U., Herlyn M: Growth factors in melanoma., Cancer Metastasis Rev 1991; 10:89-101.
139. Albino AP., Davis BM., Nanus DM: Induction of growth factor RNA expression in human malignant melanoma: Markers of transformat ion., Cancer Res 1991;51:4815-4820.
140. Quax PHA, Van Muijen GNP., Wcening-Ver-hoeff EJD., Lund LR., Dano K., Ruiter DJ., Verheijen JH: Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation., J Cell Biol 1991:115: 191-199.
141. Elder DE., Rodeck U., Thurin J., Cardillo F., Clark WH., Stewart R., Herlyn M: Antigenic profile of tumor progression stages in human mclanocytic nevi and melanomas., Cancer Res 1989;49:5091-5096.
142. Ellis DL., King LE., Nanncy LB: Increased epidermal growth factor receptor in mclanocytic lesions., J Am Acad Dermatol 1992:27:539-546.
143. Maltei S., Colombo MP., Melani C, Silvani A., Parmiani G., Herlyn M: Expression of cyto-kine/growth factors and their receptors in human melanoma and melanocytes., Int J Cancer 1994;56:853-857.
144. Maliischck B, Fomzler D., Schartl M: Melanoma formation in Xiphophorus: A model system for the role of receptor tyrosine kinases in lumorigenesis., Bioessays 1995:17: 1017-1023.
145. Schartl A., Schartl M: Tumor induction and tumor regression in Xiphophorus., In Vivo 1996:10:179-184.
146. Schartl A, Malitschek B, Kazianis S., Borow-sky R., Schartl M: Spontaneous melanoma formation in nonhybrid Xiphophorus., Cancer Res 1995:55:159-165.
147. Schartl M: Homology of melanoma-inducing loci in the genus Xiphophorus., Genetics 1990;126:1083-1091.
148. Wcllbrock C., Lammers R., Ullrich A, Schartl M: Association between the melanoma-inducing receptor tyrosine kinase Xntrk and sre family tyrosine kinases in Xiphophorus., Oncogene 1995:10:2135-2143.
149. Hcrbst RA., Weiss J., Ehnis A, Cavcnee WK, Arden KC: Loss of heterozygosity for 10q22-lOqter in malignant melanoma progression., Cancer Res 1994:54:3111-3114.
150. Rempel SA, Schwechhcimer K., Davis RL., Cavenee WK., Rosenblum ML: Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression., Cancer Res 1993:53: 2386-2392.
151. Morita R., Saito S., lshikawa J, Ogawa O., Yoshida O, Yamakawa K., Nakamura Y: Common regions of deletion of chromosome 5q., 6q and lOq in renal cell carcinoma., Cancer Res 1991:51:5817-5820.
152. Eagle LR., Brothntan AR., Williams BJ., Atkin NB, Prochownik EV: Mutation of the MXI1 gene in prostate cancer., Nat Genet 1995:9: 249-255.
153. Banga SS., Ozer H l., Park SK, Lee ST: Assignment of PTK7 encoding a receptor protein tyrosine kinase-like molecule to human chromosome 6p21.l→pl2.2 by fluorescence in situ hybridization., Cytogenet Cell Genet 1997;76:43-44.
154. Peiffer SL., Herzog TJ., Tribune DJ., Mutch DG., Gerscll DJ, Goodfcllow PJ: Allelic loss of sequences from the long arm of chromosome 10 and replication errors in endometrial cancers., Cancer Res 1995;55:1922-1926.
155. Gray IC., Phillips SMA., Lee SJ., Neoptolemos JP., Weissenbach J., Spurr NK: Loss of the chromosomal region 10q23-25 in prostate cancer., Cancer Res 1995:55:4800-4803.
156. Trvbus IM., Burgess AC, Wojno KJ, Glover TW., Macoska JA: Distinct areas of allelic loss on chromosomal regions I Op and lOq in human prostate cancer., Cancer Res 1996:56: 2263-2267.
157. Pershouse MA, Stubblefield E., Hadi A., Killary AM., Yung WKA., Steck PA: Analysis of the functional role of chromosome 10 loss in human glioblastomas., Cancer Res 1993:53: 5043-5050.
158. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang SI., Puc J., Miliarcsis C., Rodgers L., McCombie R., Bigner SH, Giovanella BC., Itt-mann M., Tvcko B., Hibshoosh H., Wigler MH., Parsons R: PTEN., a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer., Science 1997: 275:1943-1947.
159. Stcck PA., Pershousc MA, Jasser SA, Yung WKA., Lin H., Ligon AH., Langford LA., Baumgard ML., Hattier T., Davis T., Frye C, Hu R., Swedlund B., Teng DHF., Tavtigian SV: Identification of a candidate tumour suppressor gene., MMACt, at chromosome IOq23.3 that is mutated in multiple advanced cancers., Nat Genet 1997;15:356-362.
160. Li DM, Sun H:TEP1., encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor p., Cancer Res 1997;57: 2124-2129.
161. Thompson FH., Emerson J., Olson S., Weinstein R., Leavitt SA., Leong SPL., Emerson S., Trent JM., Nelson MA, Salmon SE, Taetle R: Cytogenetics of 158 patients with regional or disseminated melanoma-Subset analysis of near-diploid and simple karyotypes., Cancer Genet Cytogenet 1995:83:93-104.
162. Herbs RA, Iarson A., Weiss J., Cavenee WK, Hampton GM., Arden KC: A defined region of loss of heterozygosity at Ilq23 in cutaneous malignant melanoma., Cancer Res 1995:55:2494-2496.
163. Tomlinson IPM., Beck NE., Bodmer WF: Allele loss on chromosome 1 Iq and microsatellite instability in malignant melanoma., Eur J Cancer 1996.32A: 1797-1802.
164. Trent JM., Meyskens FL, Salmon SE., Rvs-chon K., Leong SPL., Davis JR., McGee DL: Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma., N Engl J Med 1990:322:1508-1511.
165. Morse IIG., Moore GE., Ortiz LM., Gonzales R, Robinson WA: Malignant melanoma: From subcutaneous nodule to brain metastasis., Cancer Genet Cytogenet 1992:72:16-23.
166. Shows TB, Alders M., Bennett S, Burbee D, Cartwright P., Chandrasekharappa S, Cooper P., Courseaux A., Davies C., Devignes MD., Dcvilee P., Elliott R., Evans G, Fames J., Gamer H, Gaudray P., Gerhard DS., Gessler M., Higgins M, Hummerich H., James M., Lager-crantz J., Litt M., Little P: Report of the fifth international workshop on human chromosome II mapping (1996)., Cytogenet Cell Genet 1996:74:2-52.
167. Savitsky K., Bar-Shira A., Gilad S, Rotman G., Ziv Y., Vanagaite L., Tagle DA., Smith S., Uzicl T., Sfez S, Ashkenazi M., Pecker I., Frydman M., Hamik R., Patanjali SR., Simmons A, Clines GA, Sartiel A, Gatti RA., Chessa L., Sanal O., Lavin MF., Jaspers NGJ., Shiloh Y: A single ataxia telangiectasia gene with a product similar to PI-3 kinase., Science 1995:268: 1749-1753.
168. Chandrasekharappa SC., Guru SC., Man-ickani P., Olufemi SE., Collins FS., Ernmert-Buck MR, Dcbelcnko LV., Zhuang ZP, Lu-bensky IA., Liolta LA., Crabtree JS., Wang YP., Roe BA., Weiscmann J., Boguski MS., Agarwal SK., Kester MB, Kim YS., Heppner C., Dong Qll., Spiegel AM., Bruns AL., Marx SJ: Positional cloning of the gene for multiple endocrine neoplasia-type 1., Science 1997:276: 404-407.
169. Dcbelcnko LV., Zhuang ZP., Emmert-Buck MR., Chandrasekharappa SC., Manickam P, Guru SC., Marx SJ., Skarulis MC., Spiegel AM, Collins FS., Jensen RT, Liotta L.A., Lubcnsky 1A: Allelic deletions on chromosome I Iql 3 in multiple endocrine neoplasia type 1-associated and sporadic gastrinomas and pancreatic endocrine tumors., Cancer Res 1997;57: 2238-2243.
170. Dong QH., Debelenko LV., Chandrasekharappa SC, Emmert-Buck MR., Zhuang ZP., Guru SC., Manickam P., Skarulis M., Lubcnsky IA, Liotta I.A., Collins FS., Marx SJ., Spiegel AM: Loss of heterozygosity at 11 q 13: Analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type I., J Clin Endocrinol Metab 1997:82:1416-1420.
171. Foulkes WD, Campbell IG, Stamp GWH., Trowsdale J: Loss of heterozygosity and amplification on chromosome llq in human ovarian cancer., Br J Cancer 1993:67:268-273.
172. Gabra H., Watson JEV., Taylor KJ., Mackay J, Leonard RC’F., Steel CM, Porteous DJ., Smyth JF: Definition and refinement of a region of loss of heterozygosity at I Iq23.3-q24.3 in epithelial ovarian cancer associated with poor prognosis., Cancer Res 1996:56:950-954.
173. Evans GA., Atallah S., Wang SS: Localization of a putative tumor suppressor gene in small cell lung cancer to a 400 kb region of chromosome IIq23-q24., Am J Hum Genet 1996: (suppl):A66.
174. Baysal BE., Farr JE, Rubinstein WS., Galus RA., Johnson KA., Aston CE., Myers EN., Johnson JT., Carrau R., Kirkpatrick SJ., Myssiorek D, Singh D, Saha S, Collin SM, Evans GA, James MR., Richard CW III: Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome I Iq23., Am J Hum Genet 1997;60:121-132.
175. Robertson G., Coleman A., Lugo TG: A malignant melanoma tumor suppressor on human chromosome 11., Cancer Res 1996:56:4487-4492.
176. Black DM: The genetics of breast cancer., Eur J Cancer 1994:30A: 1957-1961.
177. Buckley MF., Sweeney KJE, Hamilton JA., Sini RL., Manning DL., Nicholson Rl., deFazio A., Watts CKW., Musgrove EA, Sutherland RL: Expression and amplification of cyclin genes in human breast cancer., Oncogene 1993:8:2127-2133.
178. Dickson C., Fantl V, Gillett C., Brookes S., Bar-tek J., Smith R., Fisher C., Barnes D., Peters G: Amplification of chromosome band llq 13 and a role for cyclin D1 in human breast cancer., Cancer Lett 1995:90:43-50.
179. Peters G., Fanil V., Smith R, Brookes S., Dickson C: Chromosome 11 q 13 markers and D-type cyclins in breast cancer., Breast Cancer Res Treat 1995:33:125-135.
180. Schuuring E: The involvement of the chromosome llq 13 region in human malignancies: Cyclin Dl and EMSl arc two new candidate oncogenes-a review., Gene 1995:159:83-96.
181. Schuuring E., Verhoeven E, van Tintercn H., Petersc JL, Nunnink B., Thunnissen FBJM., Devilec P., Cornelisse CJ, van de Vijver M., Mooi WJ, Michalidcs RJAM: Amplification of genes within the chromosome I Iql3 region is indicative of poor prognosis in patients with operable breast cancer., Cancer Res 1992:52:5229-5234.
182. Strasberg-Rieber M, Rieber M: Suppression of cyclin Dl but not cdk4 or cyclin A with induction of melanoma terminal differentiation., Biochem Biophys Res C’ommun 1995: 216:422-427.
183. Becker D., Meier CB., Herlvn M: Proliferation of human malignant melanomas is inhibited by antisense oligonucleotides targeted against basis fibroblast growth factor., EMBO J 1989: 8:3685-3691.
184. Halaban R., Kwon BS., Ghosh S, Bovi PD., Baird A: bFGF as an autocrine factor for human melanomas., Oncogene Res 1988:3: 177-186.
185. Rodeck U., Becker D., Herlyn M: Basic fibroblast growth factor in human melanoma., Cancer Cells 1991:3:308-311.
186. Yayon A, Ma YS, Safran M., Klagsbrun M, Halaban R: Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase-deficient FGF receptor I: Evidence for the involvement of Src-familv kinases., Oncogene 1997:14:2999-3009.
187. Wang Y., Becker D: Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogensis and tumor growth., Nat Med 1997:3:887-893.
188. Ponnazhagan S., Hou L., Kwon BS: Structural organization of the human tyrosinase gene and sequence analysis and characterization of its promoter region., J Invest Dermatol 1994: 102:744-748.
189. Eiscn TG: The control of gene expression in melanocytes and melanomas., Melanoma Res 1996:6:277-284.
190. Feinberg AP: Genomic imprinting and gene activation in cancer., Nat Genet 1994:4:110-113
191. Issa JPJ., Baylin SB: Epigenetics and human disease., Nat Med 1996:2:281-282.
192. Barlow DP: Imprinting: A gamete’s point of view., Trends Genet 1994:10:194-199.
193. Razin A., Cedar H: DNA methylation and genomic imprinting (review)., Cell 1994,77: 473-476.
194. Tycko B: DNA methylation in genomic imprinting., Mutat Res 1997:386:131-140.
195. Ferguson-Smith AC, Rcik W., Surani MA: Genomic imprinting and cancer., Cancer Surv 1990;9:487-503.
196. Douc-Rasy S, Barrois M, Fogel S., Alioma-degbe JC., Stehclin D., Coll J., Riou G: High incidence of loss of heterozygosity and abnormal imprinting of 9 and IGF2 genes in invasive cervical carcinomas., Uncoupling of 77/9 and IGF2 expression and biallclic hy-pomethylation of 77/9., Oncogene 1996:12: 423-430.
197. Do Souza AT., Yamada T, Mills JJ., Jirtle RL: Imprinted genes in liver carcinogenesis., FASEBJ 1997:11:60-67.
198. Rondo M, Suzuki H., Ueda R, Osada H., Takagi K., Takahashi T: Frequent loss of imprinting of the W/9 gene is often associated with its ovcrcxpression in human lung cancers., Oncogene 1995:10:1193-1198.
199. Wu HR., Squire JA., Catzavelos CG., Weks-berg R: Relaxation of imprinting of human insulin-like growth factor 11 gene, IGI’2., in sporadic breast carcinomas., Biochcm Bio-phys Res Commun 1997:235:123-129.
200. Feinberg AP: A developmental context for multiple genetic alterations in Wilms’ tumor (review)., J Cell Sci 1994:18:7-12.
201. Caron H., van Sluis P., van Hoeve M, dc Rrak-er J, Bras J, Slater R., Mannens M., Voutc PA., Westcrveld A., Vcrsteeg R: Allelic loss of chromosome lp36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification., Nat Genet 1993:4:187-190.
202. Hatada I., Ohashi H., Fukushima Y., Raneko Y, Inoue M, Romoto Y., Okada A, Ohishi S, Nabetani A., Morisaki H., Nakayama M., Nii-kawa N., Mukai T: An imprinted gene p57A’: is mutated in Beckwith-Wiedcmann syndrome., Nat Genet 1996:14:171-173.
203. Matsuoka S., Thompson JS, Edwards MC., Barlelta JM, Grundy P., Ralikin LM., Harper JW., Elledge SJ., Feinberg AP: Imprinting of the gene encoding a human cyclin-depcndcnt kinase inhibitor, p57KIP2, on chromosome 11 p 15., Proc Natl Acad Sci USA 1996:93: 3026-3030.
204. Rondo M., Matsuoka S., Uchida R., Osada H., Nagatake M., Takagi R., Harper JW., Takahashi T., Elledge SJ: Selective maternal-allele loss in human lung cancers of the maternally expressed p57laP: gene at 11 p 15.5., Oncogene 1996;12:1365-1368.
205. Orlow I., lavarone A., Crider-Miller SJ., Bonilla F., Latres E., Lee MH., Gerald WL., Massaguc J., Weissman BE, Cordbn-Cardo C: Cyclin-de-pendent kinase inhibitor p57A7P2 in soft tissue sarcomas and Wilms’ tumors., Cancer Res 1996:56:1219-1221.
206. Thompson JS., Reese KJ., DcBaun MR., Perlman EJ., Feinberg AP: Reduced expression of the eyclin-dependent kinase inhibitor gene p57K, F2 in W’ilms’ tumor., Cancer Res 1996; 56:5723-5727.
207. Phillips RR., Welch DR., Miele ME., Lee J-H., Wei LL., Weissman BE: Suppression of MDA-MB-435 breast carcinoma cell metastasis following the introduction of human chromosome 11., Cancer Res 1996:56:1222-1226.
208. Ichikawa T., Ichikawa Y., Dong J, Hawkins AL., Griffin CA., Isaacs WB., Oshimura M., Barrett JC., Isaacs JT: Localization of metastasis suppressor genc(s) for prostatic cancer to the short arm of human chromosome 11., Cancer Res 1992:52:3486-3490.
209. Rinker-Schaeffcr CW, Hawkins AL., Ru N., Dong J, Stoica G, Griffin CA, Ichikawa T, Barrett JC., Isaacs JT: Differential suppression of mammary and prostate cancer metastasis by human chromosomes 17 and 11., Cancer Res 1994:54:6249-6256.
210. Dong J-T., Lamb PW, Rinker-SchaclTer CW., Vukanovic J., Ichikawa T., Isaacs JT, Barrett JC: KAU., a metastasis suppressor gene for prostate cancer on human chromosome 11 pi 1.2., Science 1995;268:884-886.
211. Burnet FM: Immunological aspects of malignant disease., Lancet 1967:i(501):1 171-1 174.
212. Burnet FM: The concept of immunological surveillance., Prog Exp Tumor Res 1970:13: 1-27.
213. Bishop JAN: Current immunotherapy for melanoma., Cancer Surv 1996:26:321-333.
214. Rocklev PF., Triefif N., Wagner RF., Tyring SR: Nonsunlight risk factors for malignant melanoma., Int J Dermatol 1994:33:398-406.
215. van Ginkel CJ., Sang RT., Blaauwgcers JL., Schatcnkerk JR., Mooi WJ., Hulscbosch JH: Multiple primary malignant melanomas in an HIV-positive man., J Am Acad Dermatol 1991:24:275-285.
216. De Placn E., Arden R., Traversal C, Gaforio JJ., Szikora JP., De Smet C, Brasseur F, van der Bcuggen P., Lethe B., Lurquin C: Structure., chromosomal localization, and expression of 12 genes of the MAGE family., Immu-nogenetics 1994;40:360-369.
217. Tefany FJ., Bametson RS., Halliday GM., McCarthy SW., McCarthy WFI: Immunocvto-chemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma., J Invest Dermatol 1991:97: 197-202.
218. Lotze MT., Chang AE., Scipp CA, Simpson C., Vetto JT, Rosenberg SA: High-dose recombinant IL-2 in the treatment of patients with disseminated cancer., Responses, treatment-related morbidity, and histologic findings., JAMA 1986;256:3117-3124.
219. Lehmann F, Marchand M., Hainaut P., Pouil-lart P., Sastre X., Ikeda H., Boon T, Coulic PG: Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection., Eur J Immunol 1995:25: 340:347.
220. Bouwes-Bavinck JN, Vermeer BJ, van der Woudc FJ., Vandcnbroucke JP., Schreuder GM., Thorogood J., Persijn GG, Claas FH: Relation between skin cancer and HLA antigens in renal-transplant recipients., N Engl J Med 1991:325:843-848.
221. Chen Q., Daniel V., Maher DW., Hcrsey P: Production of IL-10 by melanoma cells: Examination of its role in immunosuppression mediated by melanoma., Int J Cancer 1994; 56:755-760.
222. Hahnc M, Rimoldi D., Schroter M., Romero P., Schreier M., French LE., Schneider P., Bor-nand T., Fontana A., Lienard D., Cerottini JC, Tschopp J: Melanoma cell expression of Fas-(Apo-I /CD95) ligand: Implications for tumor immune escape., Science 1996:274:1363-1366.
223. Glinsky GV., Glinsky VV., Ivanova AB., Hue-ser CJ: Apoptosis and metastasis: Increased apoptosis resistance of metastatic cancer cells is associated with the profound deficiency of apoptosis execution mechanisms., Cancer Lett 1997;115:185-193.
224. Takaoka A, Adachi M, Okuda H., Sato S., Yawata A., Hinoda Y., Takayama S., Reed JC., Imai R: Anti-cell death activity promotes pulmonary metastasis of melanoma cells., Oncogene 1997; 14:2971-2977.
225. Yang HM., Reisfeld RA: Doxorubicin conjugated with a monoclonal antibody directed to a human melanoma-associated proteoglycan suppresses the growth of established tumor xenografts in nude mice., Proc Natl Acad Set USA 1988;85:1189-1193.
226. Brown JP, Woodbury RG., Han CE, Hell-strom I., Hellstrom RE: Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues., Proc Natl Acad Sci USA 1981:78:539-543.
227. Imai R., Ng AR, Ferrone S: Characterization of monoclonal antibodies to human melanoma-associated antigens., J Natl Cancer Inst 1981;66:489-496.
228. Temponi M, Gold AM., Ferrone S: Binding parameters and idiotypic profile of the whole immunoglobulin and Fab’ fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen., Cancer Res 1992;52:2497-2503.
229. Irie RF., Morton DL: Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to gan-glioside GD2., Proc Natl Acad Sci USA 1986; 83:8694-8698.
230. Livingston PO., Natoli EJ, Calves MJ., Stock-ert E, Oettgcn HF., Old LJ: Vaccines containing purified GM1 ganglioside elicit GM2 antibodies in melanoma patients., Proc Natl Acad Sci USA 1987:84:2911-2915.
231. Morton DL, Ravindranalh MH., Irie RF: Tumor gangliosides as targets for active specific immunotherapy of melanoma in man., Prog Brain Res 1994:101:251-275.
232. Moller P., Schadendorf D: Somatic gene therapy and its implications in melanoma treatment., Arch Dermatol Res 1997;289:71-77.
233. van der Bruggen P., Travcrsari C., Chomez P., Lurquin C, De Plaen E, Van de Eynde B., Rnuth A., Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma., Science 1991:254:1643-1647.
234. Brasseur F., Rimoldi D., Lienard D, Lethe B., Carrel S, Arienti F., Suter L, Vanwijck R., Bourlond A, Humblet Y., Vacca A., Conesc M., Lahayc T., Dcgiovanni G., Deraemaeckcr R., Beauduin M., Sastre X, Salamon E., Dreno B., Jager E, Rnuth A., Chevreau C, Suciu S, Lachapellc JM: Expression of MAGE genes in primary and metastatic cutaneous melanoma., Int J Cancer 1995;63:375-380.
235. Rogncr UC., Wilke R, Steck E, Rom B., Poust-ka A: The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28., Genomics 1995;29:725-731.
236. Becker JC, Gillitzcr R., Brocker EB: A member of the melanoma antigen-encoding gene (MAGE) family is expressed in human skin during wound healing., Int J Cancer 1994:58: 346-348.
237. Wang MG., Zakul R., Yi H., Rosenberg S., McBride OW: Localization of the MAGE1 gene encoding a human melanoma antigen to chromosome Xq28., Cytogenet Cell Genet 1994;67:116-119.
238. Kawakami Y, Elivahu S, Delgado CH., Robbins PF., Rivoltini L., Topalian SI., Miki T., Rosenberg SA: Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor., Proc Natl Acad Sci USA 1994:91: 3515-3519.
239. Coulie PG, Brichard V., Van PA., Wolfel T., Schneider J., Traversari C., Mattci S., De PE., Lurquin C., Szikora J P: A new gene coding for a dilTcrcntiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas., J Exp Med 1994:180:35-42.
240. Brichard V., Van Pel A., Wolfel T, Wolfel C., De PE., Lethe B., Coulie P., Boon T: The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas., J Exp Med 1993:178:489-495.
241. Wolfel T, Hauer M, Schneider J, Serrano M., Wolfel C., KJehmann-Hieb E., De PE., Han-keln T., Meyer zum Buschenfclde KH., Beach D: A pl6INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma., Science 1995:269:1281-1284.
242. Albert DM, Shadduck JA, Liu H-S, Sundcr-man FW., Wagoner MD., Papale JJ: Animal models for the study of uveal melanoma., Int Ophthalmol Clin 1980:20:143-160.
243. Bedikian AY., Legha SS., Mavligit G., Carrasco CH., Khorana S., Plager C., Papadopoulos N., Benjamin RS: Treatment of uveal melanoma metastatic to the liver: A review of the M D Anderson Cancer Center experience and prognostic factors., Cancer 1995,76:1665-1670.
244. Hungcrford JL: Uveal melanoma., Eur J Cancer 1993;29A.
245. Prescher G, Bomfeld N., Friedrichs W, Sccber S, Bechcr R: Cytogenetics of twelve cases of uveal melanoma and patterns of nonrandom anomalies and isochromosomc formation., Cancer Genet Cytogenet 1995:80:40-46.
246. Singh AD., Wang MX., Donoso LA., Shields CL., De Potter P., Shields JA: Genetic aspects of uveal melanoma: A brief review., Semin Oncol 1996:23:768-772.
247. Van Elsas A., Zerp SF., Van der Flier S., Kruse KM., Aarnoudsc C., Hayward NK., Ruiter DJ, Schrier PI: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma., Am J Pathol 1996:149:883-893.
248. Grammatico P., Re MLL, Scarpa S., Modcsti A., Del Porto G: Human malignant melanoma: Significance of chromosome abnormalities., Cancer Genet Cytogenet 1990:48:237-242.
249. Sulman EP., Tang XX., Allen C., Bicgcl JA., Pleasure DE., BrodeurGM, lkegaki N: ECK., a human L’/’/Z-relatcd gene, maps to I p36.1., a common region of alteration in human cancers., Genomics 1997:40:371-374.
250. van Haeringen A., Berman W, Nelen MR., van der Kooij-Meijs E., Hendrikse 1, Wijncn JT., Khan PM., Klasen EC., Frants RR: Exclusion of the dvsplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families., Genomics 1989:5:61-64.
251. Nakamura Y., Leppcrt M., O’Connell P., Wolff R., Holm T, Culver M., Martin C., Fujimoto E, Hoff M., Kumlin E., White R: Variable number of tandem repeat (VNTR) markers for human gene mapping., Science 1987:235: 1616-1621.
252. Carr J., MacKic RM: Point mutations in the N-ra.y oncogene in malignant melanoma and congenital naevi., Br J Dermatol 1994:131: 72-77.
253. Ray ME, Wistow G., Su YA., Meltzer PS, Trent JM: AIM I, a novel non-lens member of the betagamma-crystallin superfamily, is associated with the control of tumorigenicity in human malignant melanoma., Proc Natl Acad Sci USA 1997;94:3229-3234.
254. Limon J., Cal Cin P., Sail SNJ., Karakoukis C., Sandberg AA: Chromosome changes in metastatic human melanoma., Cancer Genet Cytogenet 1988:30:201-211.
255. Ozisik YY., Meloni AM., Altungoz O., Peier A., Karakousis C., Leong SPL, Sandberg AA: Cytogenetic findings in 21 malignant melanomas., Cancer Genet Cytogenet 1994:77:69-73.
256. Morse HG., Moore GE: Cytogenetic homogeneity in eight independent sites in a case of malignant melanoma., Cancer Genet Cytogenet 1993:69:108-112.
257. Nguyen J., Charmley P., Grody WW., Ceder-baum SD, King M-C, Gatti RA: Genetic linkage group (ARG1-D6S33-MYB) on chromosome 6q containing the arginase-1 and MYB genes., Cytogenet Cell Genet 1990:54:95-96.
258. Pathak S., Drwings HL., HsuTC: Involvement of chromosome 6 in rearrangements in human malignant melanoma cell lines., Cancer Genet Cytogenet 1983:36:573-579.
259. Petty EM., Gibson LH., Fountain JW., Bolog-nia JL., Yang-Feng TL., Housman DE., Bale AE: Molecular definition of a chromosome 9p2l germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: Implication for 9p tumor-suppressor gene(s)., Am J Hum Genet 1993:53:96-104.
260. Navtor MF., Everett MA: Involvement of the p!6INKJ (CDKN2) gene in familial melanoma., Melanoma Res 1996:6:139-145.
261. Parmitcr AH., Nowell PC: Cytogenetics of melanocvtic tumors., J Invest Dermatol 1993: 100:254S-258S.
262. Parmiter AH., Nowell PC: The cytogenetics of human malignant melanoma and premalig-nant lesions: in Nathanson L (ed): Malignant Melanoma: Biology., Diagnosis and Therapy Boston., Kluwer Academic, 1988., pp 43-61.
263. Krizman DB., Chuaqui RF, Meltzer PS., Trent JM, Duray PH, Linehan WM., Liotta LA., Ern-mcrt-Buck MR: Construction of a representa-tivccDNA library from prostatic intraepithelial neoplasia., Cancer Res 1996:56:5380-5383.
264. Dasgupta P., Linnenbach AJ, Giaccia AJ, Sta-mato TD, Reddy EP: Molecular cloning of the breakpoint region on chromosome 6 in cutaneous malignant melanoma: Evidence for deletion in the c-myb locus and translocation of a segment of chromosome 12., Oncogene 1989;4:1201-1205.
265. Johnson MR., Look AT., DeCluc JE, Valentine MB., Lowy DR: Inactivation of the NFI gene in human melanoma and neuroblastoma cell lines without impaired regulation of GTP-Ras., Proc Natl Acad Sci USA 1993:90:5539-5543.
266. Blesch A, Bosserhoff A-K., Apfel R., Belli C., Hessdoerfer B, Schmitt A., Jachimczak P, Lotlspeich F., Buettner R., Bogdahn U: Cloning of a novel malignant melanoma-derived growth-regulatory protein., MIA., Cancer Res 1994:54:5695-5701.
267. Van Greningen JJM, Blocmers HPJ., Swart GWM: Identification of melanoma inhibitory activity and other differentially expressed messenger RNAs in human melanoma cell lines with different metastatic capacity by messenger RNA differential display., Cancer Res 1995:55:6237-6243.
268. de Wit PE., Hopman AHN, Van Muijen GNP., Smeets DFCM., Beck JLM., Moesker O., Ruiter DJ.: In situ detection of supernumerary aberrations of chromosome-specific repetitive DNA targets in interphase nuclei in human melanoma cell lines and tissue sections., J Invest Dermatol 1992;98:450-458.
269. Reed JA., Loganzo F Jr, Shea CR., Walker GJ., Flores JF., Glendcning JM, Bogdany JK, Shiel MJ., Haluska FG., Fountain JW., Albino AP: Loss of expression of the /;/6/cyclin-depen-dent kinase inhibitor 2 tumor suppressor gene in mclanocytic lesions correlates with invasive stage of tumor progression., Cancer Res 1995;55:2713-2718.
270. Degen WGJ., Weterman MAJ., Van Groningen JJM., Comclisscn IMAH., Lemmers JPWM., Agterbos MA, van Kessel AG., Swart GWM., Bloemcrs HPJ: Expression of turn, a novel gene, inversely correlates with the metastatic potential of human melanoma cell lines and xenografts., Int J Cancer 1996:65: 460-465.
271. Ncdoszytko B., Mrozek K, Limon J: Absence of structural rearrangements of chromosome 11 in human primary malignant melanoma., Cancer Genet Cytogenet 1992:58:196-197.
272. Van Golen KL., Risin S., Staroselskv A., Berger D., Tainsky MA., Pathak S., Price JE: Predominance of the metastatic phenotype in hybrids formed by fusion of mouse and human melanoma clones., Clin Exp Metastasis 1996:14: 95-106.
273. Micle ME., Dc La Rosa A., Lee HL., Hicks DJ., Dennis JU., Steeg PS., Welch DR.: Suppression of human melanoma metastasis following introduction of chromosome 6 is independent ofNMEl (Nm23)., Clin Exp Metastasis 1997: 15:259-265.
274. Weiler SR., Taylor SM, Deans RJ., Kan-Mit-chell J., Mitchell MS, Trent JM: Assignment of a human melanoma associated gene MG50 (D2S448) to chromosome 2p25.3 by fluorescence in situ hybridization., Genomics 1994: 22:243-244.
275. Francia G, Mitchell SD., Moss SE., Hanby AM, Marshall JF., Hart IR: Identification by differential display of anncxin-VI., a gene differentially expressed during melanoma progression., Cancer Res 1996:56:3855-3858.
276. Easty DJ., Hcrlyn M., Bennett DC: Abnormal protein tyrosine kinase gene expression during melanoma progression and metastasis., Int J Cancer 1995;60:129-136.
277. Stancovski I., Hurwitz F., Leitner O., Ullrich A, Yardcn Y, Sela M.: Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth., Proc Nat! AcadSci USA 1991:88:8691-8695.
278. Gomze LA, Rieber MS., Richer M: PCR-mediated differential display and cloning of a melanocyte gene decreased in malignant melanoma and up-regulated with sensitization to DNA damage., DNA Cell Biol 1996:15:423-427.
279. Nishinaka Y., Ravindranath MH., Irie RF: Development of a human monoclonal antibody to ganglioside Gm; with potential for cancer treatment., Cancer Res 1996:56:5666-5671.
280. Holzmann B., Brocker EB., Lehmann JM, Ruiter DJ., Sorg C., Riethmuller G., Johnson JP: Tumor progression in human malignant melanoma: five stages defined by their antigenic phenotypes., Int J Cancer 1987:39:466-471.
281. Albelda SM., Mette SA., Elder DE., Stewart R., Damjanovich L., Herlyn M., Buck C: Integrin distribution in malignant melanoma: Association of the beta-3 subunit w ith tumor progression., Cancer Res 1990:50:6757-6764.
282. Jiang HP., Lin JJ., Su ZZ., Goldstein NL Fisher PB: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7., modulated during human melanoma differentiation, growth and progression., Oncogene 1995:11:2477-2486.
283. Atkinson B., Ernst CS., Christ BF., Ross AH., Clark WH., Herlyn M., Hcrlyn D., Maul G., Sle-plewski Z, Koprowski H: Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors., Hybridoma 1985;4:243-255.
284. Bosserhoff AK, Hein R., Bogdahn U., Bucltner R: Structure and promoter analysis of the gene encoding the human melanoma-inhibiting protein MIA., J Biol Ghent 1996:271: 490-495.
285. Steeg PS., Bcvilacqua G., Kopper L., Thorgeirs-son UP, Talmadge JE., Liotta LA., Sobcl ME: Evidence for a novel gene associated with low tuntor metastatic potential., J Natl Cancer Inst 1988:80:200-204.
286. Weterman MAJ., Ajubi N., Van Dintcr IMR., Degen WGJ., Van Muijen GNP., Ruiter DJ., Bloemers HPJ: nmb, a novel gene, is expressed in low-metastatic human melanoma cell lines and xenografts., Int J Cancer 1995: 60:73-81.
287. Van Groningen JJM., Egmond MR., Bloemers HPJ., Swart GWM: nmd., a novel gene differentially expressed in human melanoma cell lines, encodes a new atypical member of the enzyme family of lipases., FEBS Lett 1997: 404:82-86.
288. Scott G., Liang H: ppl25, AK in human melanocytes and melanoma: Expression and phosphorylation., Exp Cell Res 1995:219:197-203.